Cargando…

Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles

Nasal drug delivery has been a focus of scientific interest for decades. A number of drug delivery systems and devices are available and have been highly successful in providing better and more comfortable therapy. The benefits of nasal drug delivery are not in question. The nasal surface provides a...

Descripción completa

Detalles Bibliográficos
Autores principales: To Quoc, Thinh, Bíró, Krisztina, Pető, Ágota, Kósa, Dóra, Sinka, Dávid, Lekli, István, Kiss-Szikszai, Attila, Budai, István, Béres, Mónika, Vecsernyés, Miklós, Fehér, Pálma, Bácskay, Ildikó, Ujhelyi, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254643/
https://www.ncbi.nlm.nih.gov/pubmed/37298882
http://dx.doi.org/10.3390/molecules28114406
_version_ 1785056691670220800
author To Quoc, Thinh
Bíró, Krisztina
Pető, Ágota
Kósa, Dóra
Sinka, Dávid
Lekli, István
Kiss-Szikszai, Attila
Budai, István
Béres, Mónika
Vecsernyés, Miklós
Fehér, Pálma
Bácskay, Ildikó
Ujhelyi, Zoltán
author_facet To Quoc, Thinh
Bíró, Krisztina
Pető, Ágota
Kósa, Dóra
Sinka, Dávid
Lekli, István
Kiss-Szikszai, Attila
Budai, István
Béres, Mónika
Vecsernyés, Miklós
Fehér, Pálma
Bácskay, Ildikó
Ujhelyi, Zoltán
author_sort To Quoc, Thinh
collection PubMed
description Nasal drug delivery has been a focus of scientific interest for decades. A number of drug delivery systems and devices are available and have been highly successful in providing better and more comfortable therapy. The benefits of nasal drug delivery are not in question. The nasal surface provides an excellent context for the targeted delivery of active substances. In addition to the large nasal surface area and intensive absorption, the active substances delivered through the nose overcome the blood–brain barrier and can be delivered directly to the central nervous system. Formulations for nasal administration are typically solutions or liquid dispersed systems such as emulsions or suspensions. Formulation techniques for nanostructures have recently undergone intensive development. Solid-phase heterogeneous dispersed systems represent a new direction in pharmaceutical formulations. The wide range of possible examples and the variety of excipients allow for the delivery of a wide range of active ingredients. The aim of our experimental work was to develop a solid drug delivery system that possesses all of the above-mentioned advantageous properties. In developing solid nanosystems, we not only exploited the advantages of size but also the adhesive and penetration-enhancing properties of excipients. During formulation, several amphiphilic compounds with adhesion properties and penetration enhancing effects were incorporated. We used chlorpromazine (CPZ), which is mainly used in the treatment of psychotic disorders such as schizophrenia and bipolar disorder. Chlorpromazine has been previously investigated by our team in other projects. With the availability of previous methods, the analytical characterization of the drug was carried out effectively. Due to the frequent and severe side effects of the drug, the need for therapeutic dose reduction is indisputable. In this series of experiments, we succeeded in constructing drug delivery systems. Finely divided Na nanoparticles were formed using a Büchi B90 nanospray dryer. An important step in the development of the drug carrier was the selection of suitable inert carrier compounds. Particle size determination and particle size distribution analysis were performed to characterize the prepared nanostructures. As safety is the most important aspect of any drug formulation, all components and systems were tested with different biocompatibility assays. The tests performed demonstrated the safe applicability of our systems. The bioavailability of chlorpromazine was studied as a function of the ratio of the active ingredient administered nasally and intravenously. As described above, most nasal formulations are liquids, but our system is solid, so there is currently no tool available to accurately target this system. As a supplement of the project, a nasal dosing device was developed, corresponding to the anatomical structure; a prototype of the device was made using 3D FDM technology. Our results lay the foundation for the design and industrial scaling of a new approach to the design and production of a high-bioavailability nasal medicinal product.
format Online
Article
Text
id pubmed-10254643
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102546432023-06-10 Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles To Quoc, Thinh Bíró, Krisztina Pető, Ágota Kósa, Dóra Sinka, Dávid Lekli, István Kiss-Szikszai, Attila Budai, István Béres, Mónika Vecsernyés, Miklós Fehér, Pálma Bácskay, Ildikó Ujhelyi, Zoltán Molecules Article Nasal drug delivery has been a focus of scientific interest for decades. A number of drug delivery systems and devices are available and have been highly successful in providing better and more comfortable therapy. The benefits of nasal drug delivery are not in question. The nasal surface provides an excellent context for the targeted delivery of active substances. In addition to the large nasal surface area and intensive absorption, the active substances delivered through the nose overcome the blood–brain barrier and can be delivered directly to the central nervous system. Formulations for nasal administration are typically solutions or liquid dispersed systems such as emulsions or suspensions. Formulation techniques for nanostructures have recently undergone intensive development. Solid-phase heterogeneous dispersed systems represent a new direction in pharmaceutical formulations. The wide range of possible examples and the variety of excipients allow for the delivery of a wide range of active ingredients. The aim of our experimental work was to develop a solid drug delivery system that possesses all of the above-mentioned advantageous properties. In developing solid nanosystems, we not only exploited the advantages of size but also the adhesive and penetration-enhancing properties of excipients. During formulation, several amphiphilic compounds with adhesion properties and penetration enhancing effects were incorporated. We used chlorpromazine (CPZ), which is mainly used in the treatment of psychotic disorders such as schizophrenia and bipolar disorder. Chlorpromazine has been previously investigated by our team in other projects. With the availability of previous methods, the analytical characterization of the drug was carried out effectively. Due to the frequent and severe side effects of the drug, the need for therapeutic dose reduction is indisputable. In this series of experiments, we succeeded in constructing drug delivery systems. Finely divided Na nanoparticles were formed using a Büchi B90 nanospray dryer. An important step in the development of the drug carrier was the selection of suitable inert carrier compounds. Particle size determination and particle size distribution analysis were performed to characterize the prepared nanostructures. As safety is the most important aspect of any drug formulation, all components and systems were tested with different biocompatibility assays. The tests performed demonstrated the safe applicability of our systems. The bioavailability of chlorpromazine was studied as a function of the ratio of the active ingredient administered nasally and intravenously. As described above, most nasal formulations are liquids, but our system is solid, so there is currently no tool available to accurately target this system. As a supplement of the project, a nasal dosing device was developed, corresponding to the anatomical structure; a prototype of the device was made using 3D FDM technology. Our results lay the foundation for the design and industrial scaling of a new approach to the design and production of a high-bioavailability nasal medicinal product. MDPI 2023-05-29 /pmc/articles/PMC10254643/ /pubmed/37298882 http://dx.doi.org/10.3390/molecules28114406 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
To Quoc, Thinh
Bíró, Krisztina
Pető, Ágota
Kósa, Dóra
Sinka, Dávid
Lekli, István
Kiss-Szikszai, Attila
Budai, István
Béres, Mónika
Vecsernyés, Miklós
Fehér, Pálma
Bácskay, Ildikó
Ujhelyi, Zoltán
Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles
title Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles
title_full Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles
title_fullStr Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles
title_full_unstemmed Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles
title_short Development and Evaluation of an FDM Printed Nasal Device for CPZ Solid Nanoparticles
title_sort development and evaluation of an fdm printed nasal device for cpz solid nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254643/
https://www.ncbi.nlm.nih.gov/pubmed/37298882
http://dx.doi.org/10.3390/molecules28114406
work_keys_str_mv AT toquocthinh developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT birokrisztina developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT petoagota developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT kosadora developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT sinkadavid developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT lekliistvan developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT kissszikszaiattila developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT budaiistvan developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT beresmonika developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT vecsernyesmiklos developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT feherpalma developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT bacskayildiko developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles
AT ujhelyizoltan developmentandevaluationofanfdmprintednasaldeviceforcpzsolidnanoparticles